NCT05026008View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

March 30, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

SR1375

The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water

DRUG

Matching placebo

The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water

Trial Locations (1)

6009

Linear Clinical Research Ltd, Nedlands

All Listed Sponsors
lead

Shanghai SIMR Biotechnology Co., Ltd.

INDUSTRY

NCT05026008 - A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375 | Biotech Hunter | Biotech Hunter